INTEGRATED BIOPHARMA INC INB Income Statement

Integrated biopharma inc (INB)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10
Sales, net
13,631	14,197	11,406	13,584	14,088	12,001	10,304	-	10,575	10,800	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales, net
-	-	-	-	-	-	-	-	-	-	9,770	-	10,654	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of sales
11,779	12,171	10,007	12,004	11,995	10,671	9,085	11,099	9,106	9,752	8,765	-	9,315	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales, net
-	-	-	-	-	-	-	-	-	-	-	-	10,654	12,372	12,681	11,385	10,971	10,413	9,445	8,945	9,671	10,290	8,582	8,182	7,522	8,788	9,191	9,596	8,152	7,395	8,480	7,625	7,862	10,241	10,876	19,216	9,359	5,651	6,439
Cost of sales
-	-	-	-	-	-	-	-	-	-	-	-	9,316	10,902	10,529	9,495	9,647	9,438	8,130	8,007	8,772	9,035	7,281	7,092	6,795	7,319	7,594	8,036	6,915	6,256	6,915	6,607	6,518	7,749	8,123	12,879	7,298	4,845	5,481
Gross profit
1,852	2,026	1,399	1,580	2,093	1,330	1,219	1,466	1,469	1,048	1,005	1,706	1,339	1,470	2,152	1,890	1,324	975	1,315	938	899	1,255	1,301	1,090	727	1,469	1,597	1,560	1,237	1,139	1,565	1,018	1,344	2,492	2,753	6,337	2,061	806	958
Selling and administrative expenses
892	821	923	1,005	856	843	814	841	809	850	794	877	910	900	793	879	874	807	830	865	887	856	852	821	923	850	937	1,009	1,072	1,108	1,196	2,225	1,772	1,973	2,143	6,270	2,418	926	910
Operating income
960	1,205	476	575	1,237	487	405	625	660	198	211	829	429	570	1,359	1,011	450	168	485	73	12	399	449	269	-196	619	660	551	165	31	369	-1,207	-428	519	610	67	-357	-120	48
Other income (expense), net
Other income (expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6	-	-5	3	3	-	-	-	-
Interest expense
96	109	124	44	196	190	200	232	232	229	233	227	225	227	232	225	248	243	237	238	251	250	240	233	237	246	248	244	248	239	248	277	286	286	260	-	473	515	-
Forbearance fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,000	-	-	-	-	-
Change in fair value of derivative liabilities
-	-	-	0	0	0	9	373	54	185	-118	213	92	-364	-368	63	-130	6	-3	3	41	447	214	-40	10	82	-73	470	-174	656	-1,085	-5	-1	5	10	-	-	-	-
Realized gain on investment
49	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized gain on investment
90	-31	-24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment on investment in iBio Stock
-	-	-	-	-	-	-	107	0	168	83	36	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment charge on investment in iBio, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-139	-	-	-	0	-	-	-	-	-	-
Other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	380	-	-	-	-	-	-	-	-	-
Other income, net
0	6	21	-	25	7	-	88	9	4	0	2	10	15	16	27	15	26	24	67	116	18	9	227	-227	3	2	-	-131	-	-	-	-	-	-	39	-40	486	-448
Other income (expense), net
43	-134	-127	-117	-171	-183	-191	122	-169	-208	-434	-48	-123	-576	-584	-135	-363	-211	-216	-168	-94	215	-17	-	-	-161	-319	228	-692	797	-1,339	-	-291	-1,278	-247	-	-513	-515	-
Income before income taxes
1,003	1,071	349	458	1,066	304	214	747	491	-10	-223	781	306	-6	775	876	87	-43	269	-95	-82	614	432	-	-423	458	-	-	-	-	-	-	-	-	-	-	-	-	-
Income before income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	341	779	-527	828	-970	-1,587	-719	-759	363	-351	-870	-635	-400
Provision for income taxes
67	112	37	98	143	58	55	-71	103	338	-44	-755	68	71	126	129	54	20	28	14	24	67	29	-42	27	61	43	-	-	-	-	-	-	-	-	-	-	-	-
Income tax expense, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5	-11	-2	-	-19	-26	-	-7	-6	-5	-7
Net loss from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-640	-407
(Loss) income from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	217	406
Net income
936	959	312	360	923	246	159	818	388	-348	-179	1,536	238	-77	649	747	33	-63	241	-109	-106	547	403	-114	-450	397	298	780	-532	817	-972	-1,553	-738	-785	363	-981	-876	-423	-1
Change in fair value of derivative liability
-	-	-	-	-	-	-	-	-54	-	-	-	-92	-	-	-	0	-	-	-44	0	-447	-214	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liability
-	-	-	0	0	0	9	373	54	185	-118	213	92	-364	-368	-	-	-	-	-	-	-	-	-	10	82	-73	470	-174	656	-1,085	-5	-1	5	10	-	-	-	-
Interest expense, net of taxes
-	-	-	-	-	-	-	-	55	-	-	-	80	-	-	-	0	-	-	162	0	82	82	-	-	82	82	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of Convertible debt
-	-	-	-	-	-	-	-	9	-	-	-	10	-	-	-	0	-	-	54	0	28	28	-	-	27	27	-	-	-	-	-	-	-	-	-	-	-	-
Diluted net income
-	-	-	-	-	-	-	-	398	-	-	-	236	-	-	-	33	-	-	63	-106	210	299	-323	-450	424	480	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense on Convertible debt-CD Financial, LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-82	-	-	-	-	-	-	-	-	-
Accretion of Convertible debt - CD Financial, LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27	-	-	-	-	-	-	-	-	-
Diluted net income (loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	926	-	-	-	-	-	-	-	-	-
Diluted net income (loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-785	-	-	-	-	-
Continuing operations (in Dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.03	-0.02
Discontinued operations (in Dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.01	0.02
Basic earnings per common share (in dollars per share)
0.03	0.03	0.01	0.01	0.03	0.01	0.01	0.04	0.02	-0.02	-0.01	0.07	0.01	0.00	0.03	0.04	0.00	0.00	0.01	-0.01	-0.01	0.03	0.02	0.00	-0.02	0.02	0.01	-	-0.03	0.04	-	-	-	-0.04	-	-	-	-0.02	0.00
Diluted earnings per common share (in dollars per share)
0.03	0.03	0.01	0.01	0.03	0.01	0.01	0.04	0.01	-0.02	-0.01	0.06	0.01	0.00	0.03	0.04	0.00	0.00	0.01	0.01	-0.01	0.01	0.01	0.01	-0.02	0.01	0.01	-0.03	-0.03	0.03	0.03	-	-0.04	-0.04	-	-	-	-	-
Weighted average common shares outstanding - basic (in shares)
29,565	29,565	29,565	29,545	29,565	29,392	27,218	21,135	21,135	21,135	21,135	21,131	21,125	21,106	21,105	21,105	21,105	21,105	21,105	21,105	21,105	21,105	21,105	21,087	21,080	21,080	21,080	-	21,080	21,080	-	-	-	20,986	-	-	-	-	-
Add: Equivalent shares outstanding (in shares)
1,319	1,025	1,158	830	542	506	744	-	836	-	0	-	1,434	-	77	116	176	0	50	0	0	0	199	208	76	73	89	-	-	-	-	-	-	-	-	-	-	-	-
Shares issuable upon conversion of Convertible Debt - CD Financial, LLC (in shares)
-	-	-	-	-	-	-	-	8,230	-	0	24,692	8,230	0	0	-	0	-	0	16,461	0	8,230	8,230	-	-	8,230	8,230	-	-	-	-	-	-	-	-	-	-	-	-
Add: Stock options (in Shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	219	-	-	-	-	-	-	-	-	-
Shares issuable upon conversion of Convertible Debt - CD Financial, LLC (in Shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,230	-	-	-	-	-	-	-	-	-
Basic and diluted net income (loss) per common share (in Dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.05	-	-	-	0.02	-	-0.04	-	-
Weighted average common shares outstanding - diluted (in shares)
30,885	30,590	30,724	30,375	30,108	29,898	27,963	48,796	30,202	21,135	21,135	47,614	30,791	21,106	21,182	21,221	21,281	21,105	21,155	37,566	21,105	29,335	29,535	4,910	21,080	29,383	29,400	13,283	21,080	29,530	21,080	21,085	21,036	20,986	20,936	-	20,786	20,797	20,625